ABCL vs CDNA
AbCellera Biologics Inc. vs CareDx, Inc — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
67
Buy
VS
| Metric | ABCL | CDNA |
|---|
| AI Score |
67
|
67
|
| Price |
$11.38
|
$45.31
|
| P/E Ratio |
-21.07×
|
21.06×
|
| ROE |
-15.1%
|
-7.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
70.6%
|
| Debt / Equity |
0.15×
|
0.05×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
93.5
|
57.4
|
| Beta |
1.191
|
2.419
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus CDNA.
The committee scores are tied.
ABCL and CDNA both score 67/100.
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 93 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
CDNA Committee View
83% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 45.6% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical